Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Maglie

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Frontiers in Medicine|March 17, 2022
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre StudyCarlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 9, 2023
Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registryJoost M Meijer, Hanan Rashid, Styliani Vergadi, et al.
Frontiers in Medicine|August 7, 2023
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experienceMartina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Clinical and Experimental Dermatology|October 10, 2025
VARIANT_P: a 14-years multicentric follow-up study of atypical pemphigus variants in ItalyLavinia Quintarelli, Irene Bonanni, Elena Biancamaria Mariotti, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
The British Journal of Dermatology|August 12, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Christoph Hudemann, Holger Garn, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2023
Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)Emiliano Antiga, Rikke Bech, Roberto Maglie, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 25, 2023
S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)Emiliano Antiga, Rikke Bech, Roberto Maglie, et al.
Clinical and Experimental Dermatology|April 15, 2026
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN StudyMarina Talamonti, Edoardo Mortato, Alessandra Narcisi, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Frontiers in Medicine|March 17, 2022
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre StudyCarlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 9, 2023
Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registryJoost M Meijer, Hanan Rashid, Styliani Vergadi, et al.
Frontiers in Medicine|August 7, 2023
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experienceMartina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Clinical and Experimental Dermatology|October 10, 2025
VARIANT_P: a 14-years multicentric follow-up study of atypical pemphigus variants in ItalyLavinia Quintarelli, Irene Bonanni, Elena Biancamaria Mariotti, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
The British Journal of Dermatology|August 12, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Christoph Hudemann, Holger Garn, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2023
Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)Emiliano Antiga, Rikke Bech, Roberto Maglie, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 25, 2023
S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)Emiliano Antiga, Rikke Bech, Roberto Maglie, et al.
Clinical and Experimental Dermatology|April 15, 2026
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN StudyMarina Talamonti, Edoardo Mortato, Alessandra Narcisi, et al.
Pageof 9